Real life Egyptian experience of Daclatasvir plus Sofosbuvir with Ribavirin in na ïve difficult to treat HCV patients.

Conclusion The available evidence seems to suggest that combination therapy of (DCV/SOF with RBV) in the treatment of chronic HCV genotype IV naïve difficult to treat patients either cirrhotic or non-cirrhotic is safe and effective. Monitoring for clinical and laboratory hepatic parameters was the basis for these findings. PMID: 30009715 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30009715?dopt=Abstract

Source: Infectious Disorders Drug Targets - July 16, 2018 Category: Infectious Diseases Authors: Wahsh EA, Hussein AK, Gomaa AA, Baraka MA, Al-Deen Abead M Tags: Infect Disord Drug Targets Source Type: research